EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut mycobiome dysbiosis in digestive system cancers: immune remodeling and translational implications

LingBo Ma, Zhen Wang, Jie Mao

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1902754 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von LingBo Ma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Dysbiosis, Gastrointestinal Microbiome, Mycobiome, Fungi. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fungal dysbiosis has been reported in colorectal cancer (CRC), gastric cancer (GC), and pancreatic ductal adenocarcinoma (PDAC), but evidence strength differs substantially by tumor type and model system. Human CRC studies provide the broadest ecological evidence, including altered fungal community structure and fungal-bacterial networks. Human GC evidence is mainly cross-sectional and identifies Candida albicans as a candidate tissue-associated signal rather than a proven driver. In PDAC, human tissue studies report fungal signals, whereas causal support for Malassezia –mannose-binding lectin (MBL)–complement and fungal IL-33/type 2 immunity derives principally from mouse perturbation models. This narrative review synthesizes cancer-specific observations, fungal sensing, epithelial injury, immune remodeling, cross-kingdom interactions, and translational implications. We emphasize that low fungal biomass, contamination, transient dietary or environmental fungi, non-standardized sequencing, spatial uncertainty, and reverse causation limit interpretation. Fungal detection does not establish viability, colonization, or tumor causation. Clinical translation will require standardized controls, absolute fungal-load measurements, spatial confirmation, longitudinal cohorts, functional validation, and external testing of whether fungal features add value beyond established clinical, bacterial, metabolic, imaging, and immune markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DysbiosisGastrointestinal MicrobiomeMycobiomeFungiDigestive System NeoplasmsHumansAnimals

Stichwörter der Autor:innen

colorectal cancerfungal dysbiosisfungal-bacterial interactionsgastric cancergut mycobiomepancreatic ductal adenocarcinomatumor immune microenvironment

Autor:innen und Institutionen

  • Lanzhou University, Lanzhou, China.
  • Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China.

Zitieren

APA

Ma, L., Wang, Z., & Mao, J. (2026). Gut mycobiome dysbiosis in digestive system cancers: immune remodeling and translational implications. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1902754

Vancouver

Ma L, Wang Z, Mao J. Gut mycobiome dysbiosis in digestive system cancers: immune remodeling and translational implications. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1902754

BibTeX
@article{Ma2026,
  author = {Ma, LingBo and Wang, Zhen and Mao, Jie},
  title = {Gut mycobiome dysbiosis in digestive system cancers: immune remodeling and translational implications},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1902754}
}
Kostenlos starten →